OncoMatch/Clinical Trials/NCT06517004
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Is NCT06517004 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JWCAR201 for diffuse large b cell lymphoma.
Treatment: JWCAR201 — This is an open-label, single-arm study to investigate the efficacy and safety signals of JWCAR201 amongst subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (IHC positive)
immunohistochemistry (IHC) CD20-positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline
priorly treated by Anthracyclines
Must have received: anti-CD20-targeted therapy
priorly treated by ... anti-CD20-targeted regimens
Cannot have received: genetically engineered modified T-cell therapy
Previously treated with any genetically engineered modified T-cell therapy nor other cell-gene therapy
Cannot have received: other cell-gene therapy
Previously treated with any genetically engineered modified T-cell therapy nor other cell-gene therapy
Lab requirements
Blood counts
Adequate organ functions
Kidney function
Adequate organ functions
Liver function
Adequate organ functions
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify